Diskusjon Triggere Porteføljer Aksjonærlister

Frequencytx

Investeringer: #<Tag:0x00007f9ee5dae748>

Frequencytx.com er eit spennende firma som kom på børs i oktober 2019 og har gått 100 % siden den gang.
Dem er inni en phase 2 a på medisinen fx322 som skal reversere hørselen.

The human ear does not spontaneously restore lost or damaged hair cells, making hearing loss a permanent condition. Today, there are no FDA-approved therapeutic options for SNHL.

FX-322 is designed to treat the underlying cause of sensorineural hearing loss (SNHL) by regenerating hair cells through activation of progenitor cells already present in the cochlea.

In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word understanding. In addition, FX-322 was observed to be well-tolerated with no serious adverse effects. FX-322 is administered locally by an ear, nose, and throat specialist, using a standard in-office procedure.

In 4Q 2019 we commenced a Phase 2a study of FX-322.

3 Likes

Frequency tx har gått som ei kule oppover. Siden dei har bevist at medisinen fungerer på mennesker.
Legger med EiT lite klipp fra hjemmesiden deres. :mage:

At the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) annual meeting in September 2020, Frequency presented clinical results from a follow-up durability study of patients who had shown statistically significant improvements in word recognition scores in the Phase 1/2 study. These data showed that three of four patients maintained statistically significant improvements in word recognition between 13 - 21 months following initial dosing, while a fourth patient maintained some improvement. A fifth patient that had shown non-statistically significant improvements had returned to baseline.

The results of the Phase 2a end of study analysis, as well as those reported from the age-related hearing loss and severe SNHL studies, are expected to provide the basis for an end of Phase 2 meeting with the US Food and Drug Administration regarding potential registrational studies of FX-322.

1 Like

Investor møte 17 januar trur det kan bli en humpete vei fram til den datoen. Litt nyskjerrig på ka dei har å komme med. Håper på noe positivt :smiley:

2 Likes

Helt enig, dette er sinnsykt spennende selskap!

De har jo også en ganske bra deal med Astellas som gir finansiell stabilitet.

2 Likes

fant ut at resound gn group eit av seks firmaer innen høre apparater har gått fra kurs 33 til 487 på akkurat 10 år. Mcap 60 milliarder Er en bransje i vekst. I USA blei det solgt 4,23 mill høreapparat i 2019. Med en pris fra 1000 $ til 6000$.

1 Like

Ser jo at dei har gitt astellas salg rettigheter i Asia++ men trur at dei klarer seg med 4 millioner potensielle kunder kun i USA i året :sunglasses::ok_hand: